Phase 3 N=268 Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects
Ocular Inflammation
Primary: Ocular Inflammation — 96; 16 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women
Obesity · Fertility
Primary: Change in the Average LH Pulse Amplitude — -.04; .4 IU/L
N/A N=117 Multi-Family Group Therapy for Adult Eating Disorders
Eating Disorders
Primary: Dropout — 17; 18 participants
Phase 3 N=29 SAM-e for the Treatment of Depression in Patients With Parkinson's Disease
Parkinson's Disease · Depression
Primary: Change in Hamilton Depression Scale — 17; 17.5; 20.7; 11.4 units on a scale
Phase 1 N=39 Phase 1, TAK-648, Single-Rising Dose Study
Healthy Volunteers
Primary: Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE) — 0; 50.0; 16.7; 0 percentage of participants
Phase 4 N=20 Tumor Gene Expression in Women With Ovarian Cancer
Ovarian Cancer
Primary: Increase in SGK1 mRNA Expression Level — 1.5; 6.1 fold change
Phase 2 N=169 Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers
Ocular Inflammation
Primary: Ocular Inflammation — 21; 24; 18; 8 participants
Phase 3 N=168 A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
End Stage Renal Disease · Kidney Failure · Renal Failure
Primary: Safety Parameters — 142; 35; 75; 0 participants
Phase 3 N=268 Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects
Ocular Inflammation
Primary: Ocular Inflammation — 64; 19 participants
N/A N=3,830 Seroepidemiological Study of Pertussis and Other Infectious Diseases
Pertussis Infection
Primary: IgG — 1.254; 1.258 EU/mL(log transformed)
Phase 2 N=40 Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
Cancer
Primary: Progression Free Survival (PFS) — 8.6 Months
Phase 2 N=46 A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Head and Neck Cancer · Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) — 16 percentage of participants
Phase 1 N=48 Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) — 41.7; 33.3; 16.7; 33.3 percentage of participants
Phase 4 N=120 H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients
HIV Infections
Primary: Safety — 22; 3; 0; 18 percentage of participants
Phase 4 N=59 The Effect of Anticholinergics on Cognitive Function in the Elderly
Mental Competency · Urinary Bladder, Overactive · Cognitive Function
Primary: Hopkins Verbal Learning Test - Revised — 22.00; 24.38; 6.71; 7.83 units on a scale